Engflag

Prochic

Quick links to important sections

Prochic

Prochic_EN

Method of action: Antigout, Anti-Inflammatory

Treatment option: Gout, Fits, Behcet Syndrome

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prochic

Property Description
Active ingredient Colchicine
Form Oral tablets, capsules, or solution
Pharmacological class Anti-gout agent, Anti-inflammatory agent
General purpose Rapid relief of acute pain and swelling
Origin Naturally derived alkaloid (Colchicum autumnale)

What is Prochic and What is its Classification?

Prochic is the trade name for a highly specialized, single-ingredient medication containing the active substance, Colchicine. It is classified primarily as an anti-gout agent and belongs to the distinct pharmacological class of anti-mitotic drugs, a classification that reflects its targeted cellular mechanism. Prochic is notable for its origin, as the Colchicine component is a potent, naturally derived alkaloid historically isolated from the seeds and corm of the Colchicum autumnale plant, also known as the autumn crocus. This specific composition and origin makes it distinct from general anti-inflammatory drugs, identifying it as a highly focused therapy.

What is the Composition and Form of Prochic?

The composition of Prochic relies entirely on the potent molecule of Colchicine, formulated into pharmaceutical preparations suitable for consumption. As a single-ingredient product, its therapeutic effect is solely attributed to the action of the Colchicine molecule combined with necessary inert pharmaceutical excipients. Prochic is manufactured for oral administration and is commonly available in several high-level dosage forms, including small tablets, capsules, and an oral solution (liquid). The availability of Prochic in a dedicated oral solution, a differentiating factor from some generic Colchicine forms, provides an alternative for patients who may require liquid administration.

What is Prochic's General Purpose?

The primary general purpose of Prochic is to rapidly relieve the intense pain and swelling associated with acute, localized inflammatory events. It achieves this by functioning as a cellular disruptor, where it acts to significantly limit the ability of key inflammatory cells, specifically neutrophils, to migrate to and gather at sites of inflammation. By physically impeding the movement and activity of these cells, the medication effectively helps to interrupt the acute inflammatory cycle and quench the painful flare-up, providing targeted relief for inflammation-driven conditions.

Regulatory References

  1. MedlinePlus

What side effects are possible with Prochic?

Possible Side Effects and Safety Information: Prochic

Prochic (colchicine) is a medication with a narrow therapeutic window, meaning the difference between a therapeutic dose and a toxic dose is small. Due to this, caution is required, and patients should be aware of potential side effects and drug interactions.

Common Side Effects

The most frequently reported side effects are generally gastrointestinal in nature. If these symptoms become severe or persistent, contact your healthcare provider, as they may be early indicators of drug toxicity.

System Common Side Effects
Gastrointestinal Diarrhea, nausea, vomiting, abdominal pain
Other Headache, sore throat, tiredness

Serious Side Effects and Warnings

Severe and potentially life-threatening adverse reactions have been reported with colchicine, often associated with overdose or drug interactions that increase its levels in the body. Seek immediate medical attention if you experience any signs of the following:

  • Myopathy (Muscle Damage): Muscle pain, weakness, tenderness, especially when accompanied by dark-colored urine.
  • Blood Dyscrasias: Unusual bleeding, bruising, fever, chills, sore throat, or signs of infection, which can indicate low blood cell counts (myelosuppression).
  • Peripheral Neuropathy: Numbness, tingling, or weakness in the hands or feet.
  • Severe Allergic Reaction (Anaphylaxis): Hives, swelling of the face, lips, tongue, or throat, or difficulty breathing.

Contraindications and Drug Interactions

Prochic is contraindicated (should not be used) in patients with severe kidney or liver disease, as these conditions can lead to dangerously high levels of the drug. It is also contraindicated in patients with pre-existing blood disorders.

Serious Drug Interactions occur with medications that inhibit certain enzymes (CYP3A4) or transport proteins (P-glycoprotein), leading to increased colchicine levels and risk of toxicity. Avoid or use with caution the following classes of medications, and always inform your doctor of all medicines, supplements, and herbal products you are taking:

  • Certain antibiotics (e.g., clarithromycin, erythromycin).
  • Certain antifungals (e.g., ketoconazole, itraconazole).
  • Certain HIV medications (e.g., ritonavir, atazanavir).
  • Certain cholesterol-lowering drugs (e.g., statins, fibrates).
  • Certain heart medications (e.g., cyclosporine, diltiazem, verapamil).

Consumption of grapefruit or grapefruit juice should also be avoided as it can significantly raise the level of Prochic in the blood, increasing the risk of serious side effects.

Overdose and Emergency Response

The regulatory documentation for Prochic (Colchicine) identifies the overdose profile as severe, characterized by a potentially delayed onset of toxicity. The guidance mandates specific actions due to the drug’s narrow toxic margin and rapid systemic effects.

Overdose Scope Official Regulatory Descriptions
Documented Presentations Initial manifestations often involve severe gastrointestinal distress, including nausea, vomiting, and profuse, watery diarrhea that may be bloody. Hematologic abnormalities, such as leukopenia and thrombocytopenia, are officially cited.
Severe Outcomes Toxicity can rapidly progress to multi-organ failure, profound shock, and cardiovascular collapse. Acute kidney injury and hepatic necrosis are documented risks associated with severe exposure.
Specific Risk Groups Overdose severity is increased in patients with pre-existing renal impairment or hepatic impairment, as explicitly noted in official labeling.

Emergency Action Requirements

Immediate medical attention and hospitalization are mandated for any known or suspected overdose, regardless of initial symptom severity. Contacting emergency services or a poison control center immediately is required. Management is strictly symptomatic and supportive, as the regulatory profile confirms that no specific antidote is known for Colchicine overdose. Procedures include continuous cardiac monitoring and serial monitoring of complete blood counts, liver, and renal function.

Therapeutic Uses of Prochic

What Prochic Treats: Main Uses and Benefits

Prochic (Colchicine) is commonly used across therapeutic domains where additional symptomatic support is needed to manage heightened inflammatory responses. Its therapeutic role is commonly used for managing acute episodes and supporting the long-term prevention of recurrent manifestations, contributing to easing the overall symptom burden.

The medication is relevant in clinical settings involving inflammatory or irritative states and is commonly used for managing conditions such as acute gout flares, Familial Mediterranean Fever (FMF), and acute and recurrent pericarditis.

Quick Fact: Focus on Acute and Recurrent Symptom Management

The medication may assist with providing short-term symptomatic assistance during acute episodes of severe joint pain, swelling, and redness. In chronic conditions, the medication is relevant for managing symptoms that interfere with daily comfort, and may help patients cope more steadily with symptom fluctuations.

“Prochic is applied across domains where additional symptomatic support is needed, and supports patients during difficult episodes by easing distress.”

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Prochic — Official Regulatory Information

Eligibility Scope

Classification Populations Covered
Populations Contraindicated Patients with pre-existing blood dyscrasias (e.g., severe bone marrow depression) or known hypersensitivity to colchicine.
Patients with severe renal or hepatic impairment (e.g., severe renal failure, severe hepatic disease).
Patients with renal or hepatic impairment who are concurrently taking a P-gp inhibitor or a strong CYP3A4 inhibitor.
Age-Related Rules Use is established for children aged 4 years and older for Familial Mediterranean Fever (FMF).
Use for gout treatment or prophylaxis is not recommended in children and adolescents.
Conditional Use Groups Patients with mild to moderate renal or hepatic impairment require close monitoring for adverse effects.
Older adults require caution and close monitoring due to the potential for decreased organ function and increased risk of toxicity.
Reproductive Status Use is often contraindicated or requires caution during pregnancy and lactation, depending on the specific regulatory label. Males of reproductive potential should be advised of the risk of transient fertility impairment.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute Prohibition); Not Recommended; Conditional Use (Requires Close Monitoring); Established (Permitted Use).

Regulatory basis: Governmental Prescribing Information (FDA); Summary of Product Characteristics (EMA/SmPC).

Connection to the Overall Eligibility Profile

Official regulatory documents define Prochic (Colchicine) eligibility by establishing strict exclusion criteria focused on populations with compromised clearance pathways. The most severe constraint is the absolute contraindication for patients with both organ impairment and concomitant use of P-gp/CYP3A4 inhibitors. This framing uses clear regulatory terms like "contraindicated" and "not recommended" to delineate who can and cannot use the medicine, thereby managing the risk of toxicity in vulnerable patient groups.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Prochic

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions: P-glycoprotein (P-gp) inhibitors, Strong/Moderate Cytochrome P450 3A4 (CYP3A4) inhibitors, HMG-CoA Reductase Inhibitors (Statins), and Fibrates.
Mechanistic basis of interactions (only if stated in label): Colchicine is a substrate for P-gp and CYP3A4. Inhibition causes a pharmacokinetic interaction that results in increased systemic exposure (AUC/Cmax) of colchicine.
Timing-based interaction rules (if applicable): Subsequent treatment for an acute flare should not be repeated for at least 2 weeks.
Population-specific interaction notes (if applicable): The interaction risk is significantly heightened in patients with renal or hepatic impairment, and in elderly patients.
Interaction-related restrictions: Consumption of Grapefruit or Grapefruit Juice is explicitly restricted due to its documented effect of increasing colchicine plasma levels.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification: Contraindicated Combination (with strong P-gp/CYP3A4 inhibitors in impaired patients).
Interaction-context constraints: The absolute contraindication is explicitly conditioned on the co-presence of the interacting substance and underlying renal or hepatic impairment.

Official Interaction Statements:

The regulatory profile defines a critical pharmacokinetic interaction where inhibition of P-gp or CYP3A4 significantly increases colchicine levels. This leads to a formal Contraindicated Combination of strong inhibitors with Prochic in the presence of pre-existing renal or hepatic impairment. A separate pharmacodynamic interaction is documented with Statins and Fibrates, which carries an additive risk of myopathy. The structure reflects definitive constraints, including the avoidance of Grapefruit and timing-separation rules for acute administration.

Mechanism of Action

Prochic (Colchicine) operates through a highly specific cellular mechanism that influences the propagation of acute physiological signaling across two primary domains. The first domain involves the drug’s direct molecular interaction with the tubulin alpha/beta heterodimer, the protein subunit of microtubules. By binding to tubulin, the drug acts as a microtubule-destabilizing agent, preventing the assembly of these structural filaments. This disruption impairs the physical ability of key immune cells, primarily neutrophils, to undergo directional migration (chemotaxis) and infiltrate tissues. The second domain addresses the modulation of inflammatory signaling. The interference with cellular structure indirectly suppresses the activation and assembly of the NLRP3 inflammasome complex within immune cells. This action limits the processing of Caspase-1, thereby reducing the cellular production and secretion of the potent pro-inflammatory cytokine, Interleukin-1 beta ( IL-1beta). The resulting physiological effect of blocked cell migration and suppressed chemical signaling contributes to the overall modulation of the acute inflammatory cascade.

Dosage and Administration Information

How Prochic is Used: Official Administration Guidelines

Prochic (Colchicine) administration is governed by specific instructions, defining distinct protocols for acute episodes and long-term use. The approved route for all primary indications is oral administration, available in dosage forms such as 0.6 mg tablets or capsules, or an oral solution.

Standard Dosing and Frequency Patterns

The usage pattern depends on the clinical scenario, distinguishing between a rapid, time-sensitive course and sustained daily intake.

Usage Scenario Dosing Regimen (Adult) Frequency and Timing
Acute Gout Flare Initial 1.2 mg, followed by 0.6 mg one hour later. Max 1.8 mg for the course. Brief, two-dose regimen over one hour. Course must not be repeated for at least 72 hours.
Gout Prophylaxis 0.6 mg once or twice daily. Daily or in divided doses; maximum daily dose of 1.2 mg.
FMF Maintenance 1.2 mg to 2.4 mg daily. Daily, administered once or in divided doses.

Administration Context and Special Conditions

Prochic may be taken without regard to meals (with or without food). When utilizing the oral solution, it is required that dosing be measured with an accurate measuring device. For patients with renal or hepatic impairment, a dose reduction or an increase in the dosing interval is indicated to account for altered drug clearance. Pediatric patients with Familial Mediterranean Fever (FMF) are prescribed age-specific dosages. After completion of the acute gout regimen, the daily prophylactic dose should only be resumed after a 12-hour waiting period.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prochic

This overview summarizes the types of scientific studies that have been conducted to evaluate Prochic (Colchicine), what specific outcomes those studies measured, and where limitations or uncertainties in the research still exist, based solely on authoritative sources.

Evidence for Use in Acute Gout Flares

The research for Prochic is primarily based on controlled clinical trials (CCTs) and Randomized Controlled Trials (RCTs) that examined short-term symptom patterns in adults experiencing an acute gout attack. Researchers primarily monitored outcomes related to physical discomfort, typically assessing changes in pain levels and the measured resolution of inflammation within the first 24 to 48 hours.

More recent RCTs have focused on lower dosing strategies. The reported measurements concerning short-term pain changes in the lower dose protocols showed patterns comparable to those previously studied with higher doses. A limitation is that evidence quality varies, with some older trials demonstrating limitations in precision. Research exploring short-term changes does not provide comprehensive insight into long-term outcomes after the acute episode subsides.

Evidence for Preventing Recurrent Inflammatory Conditions

For recurrent pericarditis, research explored outcomes related to the rate of recurrence in adults. The main measurement in these trials was the time to the first recurrence. Studies monitored these outcomes over intermediate to long-term follow-up durations, typically ranging from 12 to 34 months. For gout flare prophylaxis, the research explored outcomes related to prophylaxis during the short-term window, commonly studied over the first six months after initiating a new treatment.

Evidence for Management of Familial Mediterranean Fever (FMF)

The evidence base for FMF is distinct, stemming from long-term observational studies, some spanning decades, in addition to controlled trials. This research examined outcomes related to inflammatory or irritative states and the development of long-term complications. Studies monitored the frequency and number of acute attacks in both adults and children with FMF.

What is Still Uncertain About Prochic's Research Landscape

Several areas require more comprehensive research. The follow-up durations were limited in most cardiovascular and pericarditis studies, meaning that the full picture of very long-term effects (over three years) is not fully established. Data for specific groups (e.g., the elderly over 70 years of age or those with certain high-risk comorbidities) remain insufficient or uncertain.

Key Studies & References

  1. High versus low dosing of oral colchicine for early acute gout flare: twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study (AGREE trial)
  2. Label: COLCHICINE tablet, film coated - DailyMed (NIH resource summarizing prescribing information for indications and dosing)

Frequently Asked Questions (FAQ)

Common questions about Prochic (FAQ)

Q: What is Prochic and what is it used for?

Prochic is a prescription medication that contains the active ingredient duloxetine. It belongs to a class of drugs called serotonin-norepinephrine reuptake inhibitors (SNRIs).

It is approved to treat several conditions, including:

  • Major Depressive Disorder (MDD)
  • Generalized Anxiety Disorder (GAD)
  • Diabetic Peripheral Neuropathic Pain (nerve pain in people with diabetes)
  • Fibromyalgia (chronic pain condition)
  • Chronic Musculoskeletal Pain (such as chronic low back pain or chronic pain due to osteoarthritis)

Q: How does Prochic work?

Prochic (duloxetine) works by increasing the levels of two naturally occurring chemical messengers in the brain and spinal cord: serotonin and norepinephrine.

  • For depression and anxiety, increasing these neurotransmitters helps improve mood and reduce anxiety symptoms.
  • For pain conditions like diabetic nerve pain and fibromyalgia, it is believed to affect the pain signals that travel through the central nervous system, helping to reduce the sensation of pain.

Q: What are the most common side effects of Prochic?

The most common side effects of Prochic are generally mild and often improve over time as the body adjusts to the medication. They may include:

  • Nausea
  • Dry mouth
  • Drowsiness or fatigue
  • Constipation
  • Dizziness
  • Insomnia (difficulty sleeping)
  • Increased sweating

If any side effect persists, worsens, or becomes bothersome, you should contact your healthcare provider.

Q: Can Prochic be stopped suddenly?

No, you should not suddenly stop taking Prochic without first consulting your healthcare provider. Abruptly stopping this medication can lead to withdrawal symptoms, which can include:

  • Dizziness
  • Nausea and vomiting
  • Headache
  • Irritability
  • Numbness or tingling sensations (paresthesia)
  • Anxiety
  • Sleep disturbances

If you and your healthcare provider decide to stop treatment, the dose will typically be reduced gradually over a period of time to minimize the risk of withdrawal symptoms.

How should Prochic be stored and disposed of?

How to Store and Dispose of Prochic (Colchicine)

Prochic tablets must be stored at controlled room temperature, specifically between 20^circ to 25 C (68^circ to 77 F). The medicine requires protection from both light and moisture and must be kept in a tightly closed, light-resistant container to maintain stability.

Child Safety and Disposal

It is officially required to KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN; the container must utilize a child-resistant closure. For disposal of unused or expired tablets, the preferred method is a drug take-back program. Disposal in household trash is permissible only if the tablets are mixed with an unappealing substance, sealed in a bag, and not flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagThailand

Equivalent of Prochic found in:

A-Z Index: